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ABSTRACT
Alectinib is a new generation ALK inhibitor with activity against the gatekeeper 
L1196M mutation that showed remarkable activity in a phase I/II study with 
echinoderm microtubule associated protein-like 4 (EML4) - anaplastic lymphoma 
kinase (ALK) non-small cell lung cancer (NSCLC) patients. However, alectinib 
resistance may eventually develop. Here, we found that EGFR ligands and HGF, 
a ligand of the MET receptor, activate EGFR and MET, respectively, as alternative 
pathways, and thereby induce resistance to alectinib. Additionally, the heat shock 
protein 90 (Hsp90) inhibitor suppressed protein expression of ALK, MET, EGFR, and 
AKT, and thereby induced apoptosis in EML4-ALK NSCLC cells, even in the presence 
of EGFR ligands or HGF. These results suggest that Hsp90 inhibitors may overcome 
ligand-triggered resistance to new generation ALK inhibitors and may result in more 
successful treatment of NSCLC patients with EML4-ALK.
INTRODUCTION
Non-small cell lung carcinoma (NSCLC) can 
be classified into distinct molecular subsets based on 
specific genomic alterations that drive tumorigenesis 
[1]. ALK rearrangement, most commonly EML4 -ALK, is 
detected in approximately 3–7% of unselected NSCLCs 
[2, 3]. EML4-ALK NSCLC is more frequently observed 
in patients with adenocarcinoma than with other diseases , 
in young adults than in older patients, and in non-smokers 
or light smokers (<15 packs/year) than in heavier smokers 
[4]. Crizotinib, a multiple tyrosine kinase inhibitor (TKI) 
of ALK, MET, and ROS1, is the only agent that has been 
approved for ALK-rearranged NSCLC. It shows dramatic 
clinical efficacy, with a response rate of about 60–80% and 
a progression free survival (PFS) of approximately 9–10 
months in ALK-rearranged NSCLC patients [5]. However, 
almost all patients who strongly responded to crizotinib 
acquired resistance to these agents after varying periods 
of time [6]. 
Known mechanisms for resistance to crizotinib 
include the gatekeeper L1196M mutation [6], other 
secondary ALK gene mutations (F1174L, C1156Y, 
G1202R, S1206Y, 1151-T-ins, and G1269A) [7, 8, 9, 10], 
ALK amplification [7], and activation of bypass signals 
via activation of other receptors (KIT amplification 
and epidermal growth factor receptor (EGFR) 
autophosphorylation ) [8]. We recently reported that 
receptor ligands, such as epidermal growth factor (EGF), 
heparin binding-epidermal growth factor (HB-EGF), 
and transforming growth factor-α (TGF-α) , also activate 
EGFR as a bypass signal and induce crizotinib resistance 
in EML4-ALK NSCLC cells [11]. 
Alectinib is a highly selective, new generation ALK-
TKI that also has inhibitory activity against EML4-ALK 
NSCLC cells with the gatekeeper L1196M mutation [12]. 
In a clinical trial for crizotinib-treatment naïve NSCLC 
patients with ALK rearrangement, there was a response 
rate of 93.5% to alectinib [13]. Moreover, alectinib 
demonstrated promising effects, even in the crizotinib-
treated NSCLC patients with ALK rearrangement [14]. 
While it is clear that resistance may also develop against 
this class of inhibitor, the mechanisms of resistance to 
alectinib are largely unknown. 
Heat shock protein 90 (Hsp90) is a molecular 
chaperone that plays a central role in regulating the 
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correct folding, stability, and function of numerous “client 
proteins,” including human epidermal growth factor 
receptor 2 (HER2), BRAF , mutant EGFR, and EML4-
ALK, Bcr-Abl, Raf-1, which are required for cancer cell 
survival [15, 16, 17, 18]. Hsp90 inhibition is therefore 
thought to be a promising strategy for controlling tumors, 
including those of EML4-ALK NSCLC. A natural 
product, geldanamycin, was found to directly bind to the 
ATP-binding pocket in the N-terminal domain of Hsp90 
and block the binding of nucleotides to Hsp90; hence, 
geldanamycin was found to inhibit Hsp90 function. 
The first water-soluble, semi-synthetic derivative of 
geldanamycin is 17-dimethylaminoethylamino-17-
demethoxygeldanamycin (17-DMAG) , which has shown 
excellent bioavailability and is quantitatively metabolized 
much less than other geldanamycin derivatives, such as 
17-Allylamino 17-demethoxygeldanamycin (17-AAG) 
[19, 20]. 
In the present study, we examined whether receptor 
ligands would trigger resistance to a highly selective 
ALK-TKI, alectinib. Additionally, since we previously 
demonstrated that the Hsp90 inhibitor overcame EGFR-
TKI resistance triggered by HGF, a ligand of MET, in 
EGFR-mutant lung cancer cells [21], we determined 
whether Hsp90 inhibition by 17-DMAG would overcome 
ligand-triggered alectinib resistance in ALK-rearranged 
NSCLC cells.
RESULTS
Exogenously added HGF and EGFR ligands 
induce resistance to alectinib in EML4-ALK 
NSCLC cells
Two EML4-ALK NSCLC cell lines, H2228 and 
H3122, were sensitive to crizotinib (IC50 0.3 µmol/L and 
0.06 µmol/L, respectively). These cell lines were also 
sensitive to alectinib (IC50 0.24 µmol/L and 0.03 µmol/L, 
respectively). Exogenously added HGF and EGFR ligands 
(EGF, HB-EGF, and TGF-α) slightly stimulated cell 
growth, as determined by cell counting (Supplementary 
Fig. 1), and increased cell viability was determined 
by MTT assay (Fig. 1A-B). Under these experimental 
conditions, HGF and EGFR ligands remarkably reduced 
susceptibility of H2228 and H3122 cells to alectinib. 
17-DMAG inhibits the viability of EML4-ALK 
NSCLC cells, irrespective of the presence of 
exogenously added HGF or EGFR ligands
Only the Hsp90 inhibitor 17-DMAG inhibited the 
viability of H2228 (Fig. 1C) and H3122 (Fig. 1D) cells 
Figure 1: 17-DMAG suppresses the growth of EML4-ALK NSCLC cells in the presence of HGF and EGFR ligands. 
The EML4-ALK lung cancer cell lines human H2228 and human H3122 were treated with increasing concentrations of alectinib or 
17-DMAG, with or without HGF (50 ng/mL), EGF (100 ng/mL), HB-EGF (10 ng/mL), and TGF-α (100 ng/mL), and cell viability was 
determined after 72 h by MTT assay. Data shown are representative of at least 3 independent experiments. Error bars indicate standard 
deviation (SD) of triplicate cultures. 
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in a dose-dependent manner. Importantly, 17-DMAG 
inhibited the viability of H2228 and H3122 cells, even 
in the presence of HGF or EGFR ligands. These results 
suggest that 17-DMAG may overcome alectinib resistance 
triggered by HGF or EGFR ligands, such as EGF, HB-
EGF, and TGF-α. 
17-DMAG inhibits the viability of EML4-ALK 
NSCLC cells in the presence of endogenous HGF
Recently, HGF was reported to induce resistance 
to various molecular-targeted drugs in various types of 
cancers with oncogene drivers [22, 23]. Moreover, our 
previous study reported that HGF was overexpressed in 
the EGFR mutant cancer cells that acquired resistance to 
EGFR-TKIs, indicating endogenous HGF production by 
cancer cells [24]. These findings suggest that HGF can be 
overexpressed in EML4-ALK NSCLC cells that acquire 
resistance to ALK inhibitors. 
Therefore, we next examined whether endogenously 
expressed HGF induced alectinib resistance in EML4-
ALK NSCLC cells. To assess this question, we generated 
stable HGF-gene transfectants in H2228 cells (H2228/
HGF); as a control, we generated H2228/Vec cells 
transfected with vector alone . H2228/HGF cells secreted 
high concentrations of HGF (16.0 ± 0.4 ng/mL), whereas 
the HGF concentrations secreted by H2228 and H2228/
Vec cells were under the detection limit. Consistent with 
the results of exogenously added HGF, HGF-transfected 
H2228 (H2228/HGF) cells became insensitive to alectinib 
(Fig. 2A), indicating that endogenously-expressed HGF 
also induced resistance to alectinib in EML4-ALK 
NSCLC cells. 
We further found that 17-DMAG inhibited the 
growth of both H2228/Vec and H2228/HGF cells, because 
each had an IC50 of 0.01 µmol/L (Fig. 2B). These findings 
indicate that 17-DMAG may overcome alectinib resistance 
triggered by endogenously-produced HGF.
HGF reduces alectinib susceptibility via MET 
phosphorylation, and 17-DMAG reduces 
expression of ALK and MET 
To explore the molecular mechanism by which HGF 
reduced susceptibility to alectinib and 17-DMAG inhibited 
cell growth, even in the presence of HGF, we examined 
the protein expression and phosphorylation status of 
MET, ALK, and their downstream molecules (PI3K/AKT, 
ERK1/2, and STAT3) by Western blotting (Fig. 3). Since 
Figure 2: HGF-gene transfection resulted in reducing 
susceptibility of EML4-ALK NSCLC cells to alectinib 
but not 17-DMAG. H2228/Vec (A) or H2228/HGF (B) cells 
were treated with increasing concentrations of alectinib or 17-
DMAG, and cell viability was determined after 72 h by MTT 
assay. Data shown are representative of at least 3 independent 
experiments. Error bars indicate SD of triplicate cultures.
Figure 3: 17-DMAG reduced MET protein expression 
and inhibited downstream pathways, even in the 
presence of HGF. H2228/Vec or H2228/HGF cells were treated 
with or without alectinib (0.3 μmol/L) for 2 h or 17-DMAG 
(0.3 μmol/L) for 24 h and then stimulated with or without HGF 
(50 ng/mL) for 10 minutes. The resultant cells were lysed, and 
the indicated proteins were detected by immunoblotting. Data 
shown are representative of at least 3 independent experiments.
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HGF reduced alectinib susceptibility more potently in 
H2228 compared with H3122 cells (Fig. 1A-B), we mainly 
used H2228 cells in the following experiments. H2228 
(data not shown) and H2228/Vec (Fig. 3) cells expressed 
ALK and MET proteins (ALK were phosphorylated but 
MET were not), as well as the downstream molecules 
AKT, ERK1/2, and STAT3. In the absence of HGF, 
alectinib inhibited ALK phosphorylation, thereby 
inhibiting AKT, ERK1/2, and STAT3 phosphorylation. 
In the presence of HGF, alectinib failed to inhibit 
MET, AKT, and ERK1/2 phosphorylation, although it 
inhibited ALK and STAT3 phosphorylation. These results 
suggest that HGF reduced susceptibility to alectinib by 
mainly restoring AKT and ERK1/2 pathways via MET 
activation. 
In parallel experiments, 17-DMAG decreased 
the expression of ALK and MET proteins and inhibited 
their phosphorylation and AKT, ERK1/2, and STAT3 
phosphorylation, irrespective of HGF presence. Similar 
results were observed in H2228/HGF (Fig. 3) and H3122 
cells (Supplementary Fig. 2). These results indicate that 
17-DMAG decreases protein expression of ALK and 
MET, thereby suppressing downstream signaling and 
overcoming alectinib resistance caused by HGF.
17-DMAG reduces EGFR and AKT protein 
expression and inhibits downstream pathways, 
even in the presence of EGFR ligands
We also examined the protein expression and 
phosphorylation status of EGFR and its downstream 
molecules in H2228 cells stimulated with EGFR ligands 
(Fig. 4). H2228 expressed EGFR, but EGFR was not 
constitutively phosphorylated in our experimental 
conditions. The EGFR ligands EGF, HB-EGF, and 
TGF-α remarkably induced EGFR phosphorylation. In 
these experimental conditions, alectinib failed to inhibit 
phosphorylation of EGFR or downstream AKT and 
ERK1/2, while it inhibited STAT3 phosphorylation. These 
results suggest that EGFR ligands reduced susceptibility to 
alectinib mainly by restoring AKT and ERK1/2 pathways 
via EGFR activation. 
On the other hand, 17-DMAG decreased EGFR 
protein expression, resulting in inhibition of AKT, 
ERK1/2, and STAT3 phosphorylation, irrespective of 
the presence of EGFR ligands. These results suggest that 
17-DMAG decreases EGFR protein expression, thereby 
suppressing downstream signaling and overcoming 
alectinib resistance triggered by EGFR ligands.
17-DMAG induces apoptosis of EML4-ALK lung 
cancer cells, even in the presence of HGF
We next assessed whether alectinib and 17-DMAG 
induced H2228/Vec cell apoptosis in the absence or 
presence of HGF. Alectinib induced apoptosis of H2228/
Vec cells in the absence, but not presence, of HGF (Fig. 
5). In contrast, 17-DMAG induced apoptosis in both 
the presence and absence of HGF. In a similar fashion, 
17-DMAG, but not alectinib, induced H2228/HGF cell 
apoptosis.
17-DMAG inhibits H2228 cell viability, even in 
the presence of both of HGF and EGFR ligands
Since several growth factors can be simultaneously 
produced in cancer microenvironments [25, 26], it is 
possible that HGF and EGFR ligands are co-expressed 
in EML4-ALK NSCLC cells . Crizotinib inhibits MET, 
ALK, and ROS1, and it is supposed to overcome alectinib 
resistance caused by HGF alone. We therefore examined 
the effect of 17-DMAG compared with crizotinib in the 
presence of HGF plus EGFR ligands. H2228 and H3122 
cells became insensitive to alectinib in the presence of 
HGF, TGF-α, and HGF with TGF-α (Fig. 6). These cells 
were sensitive to crizotinib in the presence of HGF, but 
they became much less sensitive to crizotinib in the 
presence of TGF-α with or without HGF. However, H2228 
and H3122 were sensitive to 17-DMAG in the presence of 
HGF, TGF-α, or HGF with TGF-α. These results suggest 
that 17-DMAG may overcome alectinib resistance, even in 
the presence of ligands for two different receptors. 
DISCUSSION
We demonstrated that ligands of MET (HGF) and 
Figure 4: 17-DMAG reduced MET protein expression 
and inhibited downstream pathways, even in the 
presence of EGFR ligands. H2228 cells were treated with or 
without alectinib (0.3 μmol/L) for 2 h or 17-DMAG (0.3 μmol/L) 
for 24 h, and then stimulated with or without EGF (100 ng/mL), 
HB-EGF (10 ng/mL), and TGF-α (100 ng/mL) for 10 min. 
The resultant cells were lysed, and the indicated proteins were 
detected by immunoblotting. Data shown are representative of at 
least 3 independent experiments.
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Figure 5: 17-DMAG induced apoptosis of EML4-ALK NSCLC cells, even in the presence of HGF. A. Apoptotic cells were 
evaluated by the 7-AAD cell viability assay , as described in the Materials and Methods. B. Quantification of apoptotic cells.
Figure 6: 17-DMAG reduced viability of EML4-ALK NSCLC cells, even in the presence of both HGF and TGF-α. 
H2228 and H3122 cells were incubated with or without alectinib (0.1 μmol/L), crizotinib (0.1 μmol/L), and/or HGF (50 ng/mL) and TGF-α 
(100 ng/mL), and cell viability was determined after 72 h by MTT assay. The percentage of cell viability is shown relative to controls 
without HGF or TGF-α treatment. * , P < 0.001 (one-way ANOVA). NS, not significant. Data shown are representative of at least 3 
independent experiments. Error bars indicate SD of triplicate cultures.
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EGFR (EGF, HB-EGF, and TGF-α) triggered resistance 
to alectinib in ALK-rearranged NSCLC cells, and that 
the Hsp90 inhibitor 17-DMAG overcame the resistance 
triggered by these receptor ligands. 17-DMAG inhibited 
protein levels of ALK, EGFR, and MET, even in the 
presence of ligand activation, and suppressed of AKT and 
ERK1/2 phosphorylation, thereby inducing apoptosis of 
ALK-rearranged NSCLC cells, irrespective of the presence 
of HGF or EGFR ligands. Since the Hsp90 inhibitor by 
itself could inhibit both driver (from rearranged ALK) and 
resistance signals (from activated receptors; MET and 
EGFR), it may be an ideal agent for overcoming ligand-
triggered alectinib resistance in ALK-rearranged NSCLC. 
Activation of bypass signals is a common resistance 
mechanism for targeted drugs. For example, EGFR-TKI 
resistance could be caused by MET amplification [27], 
HGF-triggered MET activation [23], Gas6-triggered AXL 
activation [28], and HER2 amplification [29] in EGFR 
mutant lung cancer. BRAF inhibitor resistance could be 
caused by HGF-triggered MET activation [30], and IGF-
1 triggered its receptor activation [31] in BRAF mutant 
melanoma. Crizotinib resistance could be caused by EGFR 
ligand-triggered EGFR activation [11], and stem cell 
factor (SCF)-triggered amplified cKIT activation [8] in 
EML4-ALK NSCLC. Therefore, HGF and EGFR ligands 
may be common resistance triggers that activate bypass 
survival signal via their receptor activation. The results 
in the present study are consistent with previous research 
indicating that alectinib resistance was induced by HGF 
and EGFR ligands. 
Previous studies reported that several signaling 
pathways, including PI3K/AKT, MEK/ERK, and STAT3, 
are essential for survival and/or resistance to ALK 
inhibitors in ALK-rearranged NSCLC cells [12, 32]. 
Accordingly, we found that alectinib inhibited STAT3 
and ALK phosphorylation. In the presence of alectinib, 
HGF or EGFR ligands restored AKT and ERK1/2, but not 
STAT3, phosphorylation and thereby made EML4-ALK 
cells insensitive to alectinib. These observations indicate 
that, when activated by their ligands, AKT and ERK 
signals from MET or EGFR play pivotal roles in alectinib 
resistance of EML4-ALK NSCLC cells. 
It is of interest in the present study that HGF and 
EGFR ligands induced not only ALK-TKI resistance but 
also increased cell growth of EML4-ALK NSCLC cells. 
HGF and EGFR ligands also induced morphological 
change of H2228 cells (Supplementary Fig. 3). Therefore, 
these receptor ligands may modulate various cancer 
phenotypes of EML4-ALK NSCLC cells. HGF-MET 
and EGFR-ligands-EGFR axises play pivotal roles in 
progression of various types of tumors (33, 34). We 
are planning further studies to explore the molecular 
mechanisms of this morphological change and co-relation 
between the expression of receptor ligands in patient 
specimens and clinical characteristics in ALK-rearranged 
NSCLC. 
Inter- and/or intra-tumor heterogeneity is a critical 
obstacle in cancer therapy with targeted drugs [35]. 
This is also the case in ALK-TKI resistance. Intra-
tumor heterogeneity caused by crizotinib resistance 
results from the L1196M gatekeeper ALK mutation, 
and other ALK secondary C1156Y mutations co-existed 
in malignant pleural effusion of a patient who acquired 
crizotinib resistance [6]. Moreover, activation of different 
two receptors, EGFR and amplified KIT (both of which 
could induce crizotinib resistance), also co-existed in one 
crizotinib-resistant tumor [8]. 
Hsp90 inhibitors have been reported to overcome 
crizotinib resistance caused by several mechanisms, 
including ALK amplification, L1196M gatekeeper ALK 
mutation, other secondary ALK mutations (including 
F1174L), and epithelial to mesenchymal transition. 
Furthermore, we demonstrated that the Hsp90 inhibitor 
may overcome alectinib resistance, even when ligands 
of MET and EGFR co-exist . A new generation of Hsp90 
inhibitors, including ganetespib, has recently been 
developed, and remarkable efficacy has been reported 
in a co-clinical model and early phase clinical studies 
[36]. Therefore, Hsp90 inhibition using new generation 
inhibitors may be a promising strategy to treat ALK-
rearranged NSCLCs that acquire resistance to alectinib. 
MATERIALS AND METHODS
Cell culture
The H2228 human lung adenocarcinoma cell line, 
with EML4-ALK fusion protein variant3 (E6;A20), 
was purchased from the American Type Culture 
Collection (Manassas, VA ). The H3122 human lung 
adenocarcinoma cell line, with EML4-ALK fusion protein 
variant1 (E13;A20), was kindly provided by Dr. Jeffrey 
A. Engelman of the Massachusetts General Hospital 
Cancer Center (Boston, MA) [37]. H2228 and H3122 
cells were cultured in RPMI-1640 medium supplemented 
with 5% fetal bovine serum (FBS), penicillin (100 U/
mL), and streptomycin (50 μg/mL) in a humidified CO2 
incubator at 37°C. All cells were passaged for less than 3 
months before renewal from frozen, early-passage stocks 
obtained from the indicated sources. Cells were regularly 
screened for Mycoplasma using a MycoAlert Mycoplasma 
Detection Kit (Lonza , Basel, Swiss). 
Reagents
Alectinib, crizotinib, and 17-DMAG were purchased 
from Seleck Chemicals (Houston, TX). Recombinant EGF, 
TGF-α, and HB-EGF were purchased from R&D Systems 
(Minneapolis, MN). Recombinant HGF was prepared as 
described in a previous study [38]. 
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Cell growth assay
Cell proliferation was measured using the 
3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl terazolium 
bromide (MTT) dye reduction method [39]. Tumor 
cells were harvested at 80% confluence, seeded at 2 
× 103 cells per well in 96-well plates, and incubated in 
appropriate medium for 24 h. Several concentrations of 
alectinib, crizotinib, 17-DMAG, and/or EGF, TGF-α, HB-
EGF, and HGF were added to each well, and incubation 
continued for another 72 h. Fifty μL MTT (2 mg/mL; 
Sigma, St.Louis, MO) was added to each well, followed 
by incubation for 2 h at 37°C. The media were removed 
and the dark blue crystals in each well were dissolved 
in 100 μL of dimethyl sulfoxide (DMSO). Absorbance 
was measured with an MTP-120 Microplate reader 
(Corona Electric , Hitachinaka, Ibaraki, Japan) at test and 
reference wavelengths of 550 and 630 nm, respectively. 
The percentage growth was calculated relative to untreated 
controls. Each assay was carried out at least in triplicate, 
with results based on 3 independent experiments. 
HGF-gene transfection
One day before transfection, aliquots of 1 × 105 
H2228 cells in 1 mL of antibiotic-free medium were 
plated on 6-well plates. The full-length HGF cDNA 
cloned into the BCMGSneo expression vector [40] was 
transfected using Lipofectamine 2000 according to the 
manufacturer’s instructions. After incubation for 24 h, 
the cells were washed with phosphate buffered saline 
(PBS) and incubated for an additional 72 h in antibiotic-
containing medium. Then, the cells were selected in G418 
sulfate (Calbiochem, Jolla, CA). After limiting dilution, 
the HGF-producing cells, H2228/HGF, were established. 
HGF production by H2228/HGF was confirmed by 
enzyme linked immunosolvent assay (ELISA) .
HGF production 
Cells (2 × 105) were cultured in RPMI-1640 medium 
with 10% FBS for 24 h. The cells were washed with PBS 
and incubated for 48 h in 2 mL of RPMI-1640 medium 
with 10% FBS. Then, culture medium was harvested 
and centrifuged, and the supernatant was stored at –70°C 
until analysis. HGF concentrations were determined by 
IMMUNIS HGF EIA (Institute of Immunology, Tokyo) 
according to the manufacturer’s protocols. All samples 
were run in duplicate. Color intensity was measured at 
450 nm using a spectrophotometric plate reader. Growth 
factor concentrations were determined by comparison with 
standard curves, and the HGF detection limit was 100 pg/
mL. 
Apoptosis assay
Cell apoptosis induced by alectinib and 17-DMAG 
was measured by the PE Annexin V Apoptosis Detection 
Kit I (BD Biosciences, San Jose, CA) which detects and 
quantifies apoptotic cells with phycoerythrin (PE) Annexin 
V and 7-amino-actinomycin (7-AAD) staining. Cells 
were analyzed on a FACSCalibur flow cytometer with 
CellQuest software (Becton Dickinson, Franklin Lakes, 
NJ).
Western blotting
Sodium dodesyl sulfate (SDS) polyacrylamide 
gels (Bio-Rad , Hercules, CA) were loaded with 40 μg 
total protein per lane; following electrophoresis, the 
proteins were transferred onto polyvinylidene difluoride 
membranes (Bio-Rad ), which were incubated with 
Blocking One (Nacalai Tesque, Kyoto, Japan ) for 1 h at 
room temperature, followed by overnight incubation at 4°C 
with anti-ALK (C26G7), anti-phospho-ALK (Tyr1604), 
anti-phospho-EGFR (Tyr1068), anti-STAT3 (79D7), 
anti-phospho-STAT3 (Y705), anti-AKT, anti-phospho-
AKT (Ser473), anti-ErbB4 (111B2), anti-phospho-ErbB4 
(Tyr1284), anti-MET (25H2), anti-phospho-MET (Y1234/
Y1235) (3D7), or anti-β-actin (13E5) antibodies (1:1,000 
dilution each; Cell Signaling Technology , Danvers, MA), 
or with anti-human EGFR (1 μg/mL), anti-human/mouse/
rat extracellular signal-regulated kinase (Erk)1/Erk2 
(0.2 μg/mL), or anti-phospho-Erk1/Erk2 (T202/Y204) 
(0.1 μg/mL) antibodies (R&D Systems ). After washing 
3 times, the membranes were incubated for 1 h at room 
temperature with secondary antibodies (horseradish 
peroxidase-conjugated species-specific antibodies). 
Immunoreactive bands were visualized with 
SuperSignal West Dura Extended Duration Substrate 
Enhanced Chemiluminescent Substrate (Pierce, Osaka, 
Japan ). Each experiment was independently carried out 
at least 3 times. 
Statistical analysis
Differences were analyzed by one-way ANOVA. 
All statistical analyses were carried out using GraphPad 
StatMate 4 (GraphPad Software, Inc ., San Diego, CA). P 
< 0.05 was considered significant. 
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